🇺🇸 FDA
Patent

US 12241067

Compounds and methods for reducing LRRK2 expression

granted A61KA61K31/7115A61K31/712

Quick answer

US patent 12241067 (Compounds and methods for reducing LRRK2 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
25
CPC classes
A61K, A61K31/7115, A61K31/712, A61K31/7125, A61K47/02